https://doi.org/10.55788/2de236ac
“Little is known on the mental health in patients with inflammatory arthritis,” Ms Sofie Bech Vestergaard (Aarhus University Hospital, Denmark) informed [1]. This is why the Danish cross-sectional study focused on the possible effect of anxiety and depression on self-management behaviour in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA). “We know that poor mental health is associated with overall poor health, that is why it is such an important area,” Prof. Jette Primdahl (IRS Danish Hospital for Rheumatic Diseases, Denmark) underlined in her comment on the study [2].
Over 12,000 patients identified from the Danish Rheumatology database and National Patient Registry completed an electronic questionnaire [1]. Patients had a mean age of 62 and a disease duration of 12 years. Women represented 63.4% of the study population. Possible anxiety and depression were both defined by a score between 8 and 10 on the Hospital Anxiety and Depression Scale (HADS), while a score of ≥11 was used for definite cases.
The prevalence of anxiety varied among the different groups: 34.5% in SpA, 32.1% in PsA, and 22.1% in RA. Depression was present in somewhat similar proportions, with a prevalence of 27.2% in PsA, 26.4% in SpA, and 18.6% in RA. Being a woman, having basic education, being under 55 years, or being recently diagnosed (less than 3 years) was associated with a higher prevalence of anxiety and depression.
“Patients with clinical levels of anxiety and depression symptoms were more likely to have low levels of self- management behaviour for all included measures,” Ms Vestergaard revealed. Thus, treatment adherence, patient activation in healthcare, and physical activity were significantly lower in those suffering from anxiety or depression. Moreover, Ms Vestergaard highlighted that patients with definite depression had marked difficulties handling new situations concerning their health condition, compared with patients without depression (OR 7.09; 95% CI 6.11–8.22). “We need a systematic approach to identify those patients who suffer from anxiety and depression and refer them appropriately. We may need to develop new interventions to dedicate to these patients,” Prof. Primdahl advocated in light of these results [2].
- Vestergaard SB, et Self-management behaviour, anxiety and depression in patients with inflammatory arthritis – a cross-sectional nationwide study among >12,000 Danish patients. OP0176, EULAR 2023, 31 May–3 June, Milan, Italy.
- Primdahl Press conference, EULAR 2023, 31 May–3 June, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Disease activity-guided dose reduction may be a long-term option for stable RA Next Article
AI almost as successful as experts in predicting early RA »
« Disease activity-guided dose reduction may be a long-term option for stable RA Next Article
AI almost as successful as experts in predicting early RA »
Table of Contents: EULAR 2023
Featured articles
Late-breaking Oral Abstracts
Selective JAK1/TYK 2 inhibitor effective in patients with difficult-to-treat RA
Novel 2-drug combo improves treatment possibilities for patients with refractory gout
Dazodalibep improves dryness, fatigue, and pain in patients with Sjögren’s syndrome with a high symptom burden
COVID-19: Young adults with auto-immune diseases have different risks than their healthy counterparts
RA in 2023
Poly-refractory RA: not common, but still present
AI almost as successful as experts in predicting early RA
Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression
Disease activity-guided dose reduction may be a long-term option for stable RA
Cardiovascular safety of JAK inhibitors: reassuring results from a real-world study
Spondylarthropathies: New Developments
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression
Vascular inflammation may be characteristic of PsA
Obesity in PsA is increasingly affecting male patients
PsA patients: highest risk of developing NAFLD
What is Hot in Osteoarthritis
Lorecivivint shows long-term benefits for severe knee OA
Methotrexate lowers pain in inflammatory hand OA
Systemic Sclerosis: State of the Art
Targeted DMARDs advantageous in SSc patients with pre-capillary pulmonary hypertension
Osteoporosis: New Data
Drugs for osteoporosis: time to reach fracture risk reduction varies
Romosozumab: the new option for glucocorticoid-induced osteoporosis with high fracture risk?
Best of the Posters
Therapy with biological DMARDs shows no correlation with fracture risk in RA
Basic Science
In vitro and in vivo studies confirm the role of regulatory volume decrease
Related Articles
August 14, 2020
Anifrolumab achieves rapid and durable BICLA-response
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy